Davì G, Averna M, Novo S, Barbagallo C M, Mogavero A, Notarbartolo A, Strano A
Patologia Medica, Università di Palermo, Italy.
Atherosclerosis. 1989 Sep;79(1):79-83. doi: 10.1016/0021-9150(89)90036-1.
An increased susceptibility of platelets to aggregation induced by various agents and a higher production of active arachidonate metabolism have been described in type IIa hypercholesterolemia. This study was designed to evaluate whether changes in platelet function could be observed in hypercholesterolemic patients after synvinolin therapy. Administration of synvinolin to 12 type IIa hypercholesterolemic patients for 24 weeks had a lipid lowering effect and resulted in a marked reduction of platelet aggregation and thromboxane formation induced by collagen and arachidonate. Maximum response was achieved at 4-8 weeks and lipid lowering effects at 2 weeks. This finding indicates that platelet changes cannot be explained by a direct effect of synvinolin on platelets, and the antiplatelet response may therefore depend on platelet membrane lipid composition changes, particularly in the platelet cholesterol content of platelet membranes, following substantial reductions of total plasma cholesterol and LDL-cholesterol.
在IIa型高胆固醇血症中，已发现血小板对各种诱导剂诱导的聚集敏感性增加，且活性花生四烯酸代谢产物生成增多。本研究旨在评估辛伐他汀治疗后高胆固醇血症患者的血小板功能是否会发生变化。对12例IIa型高胆固醇血症患者给予辛伐他汀治疗24周，具有降脂作用，并显著降低了胶原和花生四烯酸诱导的血小板聚集及血栓素生成。在4 - 8周时达到最大反应，2周时出现降脂作用。这一发现表明，血小板变化不能用辛伐他汀对血小板的直接作用来解释，因此抗血小板反应可能取决于血小板膜脂质组成的变化，特别是在血浆总胆固醇和低密度脂蛋白胆固醇大幅降低后，血小板膜中血小板胆固醇含量的变化。
